Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach?
Mantle cell lymphoma (MCL), a type of B-cell non-Hodgkin lymphoma characterized by the t(11;14)(q13q32) translocation, is a clinically heterogenous disease which can range from indolent to highly aggressive. Numerous prognostic factors have been identified, including blastoid histology, the Mantle C...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/12/7/1134 |
| _version_ | 1797445955617816576 |
|---|---|
| author | Lindsay Hammons Timothy S. Fenske |
| author_facet | Lindsay Hammons Timothy S. Fenske |
| author_sort | Lindsay Hammons |
| collection | DOAJ |
| description | Mantle cell lymphoma (MCL), a type of B-cell non-Hodgkin lymphoma characterized by the t(11;14)(q13q32) translocation, is a clinically heterogenous disease which can range from indolent to highly aggressive. Numerous prognostic factors have been identified, including blastoid histology, the Mantle Cell Lymphoma International Prognostic Index (MIPI) score, high proliferation index, p53 deletions and/or mutations, complex karyotype, minimal residual disease, and several others. However, using these prognostic factors to guide treatment selection has largely remained elusive. Given the heterogeneous behavior of this disease and varying patient characteristics, we suggest that the time has come for a more risk-adapted approach to this disease. In this article, we review the numerous prognostic factors that have been described for MCL, both at the time of diagnosis and following first-line treatment. We then propose a risk-adapted approach to first-line therapy for MCL, which would reserve intensive therapy for the highest risk patients and spare others excessive toxicity. |
| first_indexed | 2024-03-09T13:33:16Z |
| format | Article |
| id | doaj.art-823b5846455843ee928b073d0eca4c24 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-09T13:33:16Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-823b5846455843ee928b073d0eca4c242023-11-30T21:15:27ZengMDPI AGJournal of Personalized Medicine2075-44262022-07-01127113410.3390/jpm12071134Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach?Lindsay Hammons0Timothy S. Fenske1Department of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USADepartment of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USAMantle cell lymphoma (MCL), a type of B-cell non-Hodgkin lymphoma characterized by the t(11;14)(q13q32) translocation, is a clinically heterogenous disease which can range from indolent to highly aggressive. Numerous prognostic factors have been identified, including blastoid histology, the Mantle Cell Lymphoma International Prognostic Index (MIPI) score, high proliferation index, p53 deletions and/or mutations, complex karyotype, minimal residual disease, and several others. However, using these prognostic factors to guide treatment selection has largely remained elusive. Given the heterogeneous behavior of this disease and varying patient characteristics, we suggest that the time has come for a more risk-adapted approach to this disease. In this article, we review the numerous prognostic factors that have been described for MCL, both at the time of diagnosis and following first-line treatment. We then propose a risk-adapted approach to first-line therapy for MCL, which would reserve intensive therapy for the highest risk patients and spare others excessive toxicity.https://www.mdpi.com/2075-4426/12/7/1134mantle cell lymphomanon-Hodgkin lymphomaminimal residual diseaserisk-adapted therapy |
| spellingShingle | Lindsay Hammons Timothy S. Fenske Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach? Journal of Personalized Medicine mantle cell lymphoma non-Hodgkin lymphoma minimal residual disease risk-adapted therapy |
| title | Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach? |
| title_full | Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach? |
| title_fullStr | Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach? |
| title_full_unstemmed | Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach? |
| title_short | Treatment of Mantle Cell Lymphoma in the Frontline Setting: Are We Ready for a Risk-Adapted Approach? |
| title_sort | treatment of mantle cell lymphoma in the frontline setting are we ready for a risk adapted approach |
| topic | mantle cell lymphoma non-Hodgkin lymphoma minimal residual disease risk-adapted therapy |
| url | https://www.mdpi.com/2075-4426/12/7/1134 |
| work_keys_str_mv | AT lindsayhammons treatmentofmantlecelllymphomainthefrontlinesettingarewereadyforariskadaptedapproach AT timothysfenske treatmentofmantlecelllymphomainthefrontlinesettingarewereadyforariskadaptedapproach |